Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry.

Abstract

Background In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention-related ischemic complications without increasing major bleeding. This study was performed to examine cangrelor use and transition to oral P2Y12 inhibitors in routine clinical practice. Methods and Results The CAMEO (Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes) registry is a multicenter, retrospective observational study of platelet inhibition strategies for patients with myocardial infarction undergoing percutaneous coronary intervention. In phase 1, data were collected on consecutive patients with myocardial infarction (n=482) treated with any P2Y12 inhibitor to understand cangrelor use by hospital. In phase 2, data were collected in a 2:1 (cangrelor-: non-cangrelor-treated) ratio of patients with myocardial infarction (n=873). In phase 1, cangrelor use varied across hospitals (overall, 50.4% [range, 6.0%-100%]). Of patients receiving cangrelor in both phases (n=819), 3.3% received either the bolus or infusion only. Cangrelor was infused for a median of 121 (76-196) minutes; and 38.3% received an infusion for <2 hours. Most patients transitioned from cangrelor to ticagrelor (ticagrelor, 85.3%; clopidogrel, 9.5%; prasugrel, 5.2%). Many patients (16.4%) had a >1-hour gap between cangrelor cessation and oral P2Y12 inhibitor initiation; this was highest among those transitioned to clopidogrel (56.6% versus 34.5% prasugrel versus 10.8% ticagrelor; P<0.001). Only 27.3% were dosed with cangrelor and transitioned to an oral P2Y12 inhibitor in a fashion consistent with the pivotal trials and US Food and Drug Administration label. Conclusions This multicenter registry demonstrated interhospital variability in how cangrelor was administered and transitioned to an oral P2Y12 inhibitor. These findings highlight opportunities for optimization of cangrelor dosing, infusion duration, and transition of care from the catheterization laboratory to the ward setting.

• Authors: Jennifer A Rymer, Deepak L Bhatt, Dominick J Angiolillo, Miguel Diaz, Kirk N Garratt, Ron Waksman, Laura Edwards, Gudaye Tasissa, Khalid Salahuddin, Hijrah El-Sabae, Carmen Dell'Anna, Linda Davidson-Ray, Jeffrey B Washam, E Magnus Ohman, Tracy Y Wang
• Journal: Journal of the American Heart Association (J Am Heart Assoc) Vol. 11 Issue 11 Pg. e024513 (06 07 2022) ISSN: 2047-9980 [Electronic] England
• PMID: 35621210 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Adenosine Monophosphate
• cangrelor
• Clopidogrel
• Prasugrel Hydrochloride
• Ticagrelor

Topics

• Adenosine Monophosphate (analogs & derivatives)
• Clopidogrel (therapeutic use)
• Humans
• Myocardial Infarction (chemically induced, drug therapy)
• Percutaneous Coronary Intervention (adverse effects, methods)
• Platelet Aggregation Inhibitors (adverse effects)
• Prasugrel Hydrochloride (therapeutic use)
• Purinergic P2Y Receptor Antagonists (adverse effects)
• Registries
• Ticagrelor (therapeutic use)
• Treatment Outcome